Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ADMA Biologics Inc (NASDAQ:ADMA)

5.40
Delayed Data
As of 12:59pm ET
 -0.1699 / -3.05%
Today’s Change
4.15
Today|||52-Week Range
9.58
-33.08%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$71.1M

Company Description

ADMA Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of human plasma and plasma-derived therapeutics. It operates through the Plasma Collection Center and Research and Development segments. The Plasma Collection Center segment comprises of operations in Georgia. The Research and Development segment involves plasma development operations in New Jersey. The company's targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.

Contact Information

ADMA Biologics, Inc.
465 State Route 17
Ramsey New Jersey 07446-2012
P:(201) 478-5552
Investor Relations:

Employees

Shareholders

Mutual fund holders7.62%
Individual stakeholders7.54%
Other institutional26.91%

Top Executives

Adam S. GrossmanPresident, CEO & Class II Director
Brian LenzChief Financial & Principal Accounting Officer, VP
James MondChief Scientific & Medical Officer
Theresa GwaltneySenior Director-Supply Chain Operations
James HauertSenior Vice President-Commercialization & Strategy